All In Biotech

Drug Trial Radar · NCT06324357

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) Alone or in Combination With Other Agents for the Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC), Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC), or Metastatic Colorectal Cancer (mCRC)

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 910 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

910

Planned (sponsor's estimate)

Start

Jun 28, 2024

Primary completion

Jan 8, 2029

Study completion Jan 8, 2029

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Mar 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken alone or together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1), with trastuzumab with or without capecitabine, with zanidatamab with or without docetaxel, or with mFOLFOX6 (with or without trastuzumab). Another purpose is to check whether zongertinib alone and in combination with other treatments can make tumours shrink. Zongertinib inhibits HER2. HER2 causes cancer cells to grow. In this study, participants receive treatment in cycles. Study participants are treated with zongertinib alone or in combination with other treatments. This study has 2 parts. In Part 1, participants in different groups receive increasing doses of zongertinib. In Part 2, participants are put into different groups by chance. Each group receives a different dose of zongertinib. Every participant has an equal chance of being in each group. During the study, the participants visit the study site regularly. In this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken alone or together with other treatments. To find this out, researchers look at certain severe health problems that a number of participants have. The doctors regularly check the size of the tumour with imaging methods (CT/MRI) during the study. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Metastatic Breast Cancer
  • Metastatic Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Esophageal Adenocarcinoma
  • Colorectal Cancer

Interventions

  • ZongertinibDrug

    Zongertinib

  • Trastuzumab deruxtecanDrug

    Trastuzumab deruxtecan

  • Trastuzumab emtansineDrug

    Trastuzumab emtansine

  • TrastuzumabDrug

    Trastuzumab

  • CapecitabineDrug

    Capecitabine

  • mFOLFOX6Drug

    mFOLFOX6 (oxaliplatin, calcium folinate, 5-fluorouracil)

  • zanidatamabDrug

    zanidatamab

  • DocetaxelDrug

    Docetaxel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose escalation (Phase Ib): Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation periodTime frame: up to 21 days
  2. Dose optimization and justification (Phase II): Objective response (OR)Time frame: up to 50 months

Locations

105 sites in 10 countries. Site status is shown where the registry gives one.

  • The Oncology Institute of Hope and Innovation

    Cerritos, California · Recruiting

  • Ellison Medical Institute

    Los Angeles, California · Recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • University of California Los Angeles

    Los Angeles, California · Recruiting

  • University of California Irvine

    Orange, California · Recruiting

  • Sharp Memorial Hospital

    San Diego, California · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • Helios CR Inc

    Lakeland, Florida · Recruiting

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida · Recruiting

  • Orchard Healthcare Research Inc.- Skokie

    Skokie, Illinois · Recruiting

  • Community Health Network

    Indianapolis, Indiana · Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Not yet recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

  • New York Cancer & Blood Specialists

    Shirley, New York · Recruiting

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • Avera Cancer Institute

    Sioux Falls, South Dakota · Recruiting

  • Baptist Cancer Center - Memphis

    Memphis, Tennessee · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology, Pllc

    Nashville, Tennessee · Recruiting

  • The Methodist Hospital Research Institute

    Houston, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Inova Schar Cancer Institute

    Fairfax, Virginia · Recruiting

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Hôpital Vivalia De Libramont

    Libramont-Chevigny, Belgium · Recruiting

  • Centre Hospitalier Universitaire de Liège

    Liège, Belgium · Terminated

  • CHU UCL Namur

    Namur, Belgium · Recruiting

  • Jilin Province Cancer Hospital

    Changchun, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, China · Recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

    Hangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

  • Tianjin Cancer Hospital

    Tianjin, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.